Exchange: NASDAQ·Updated 11:53 AM EDT
GPCR logo

GPCRStructure Therapeutics Inc - ADR

$49.61
$0.26
(0.53%)
Today
EarningsAug 6
Mkt Cap$3.51B
Vol183,480.00
News
all
press releases
Does EU Approval of Wegovy Pill Change NVO's Competitive Story?
Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.
Zacks
More News
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.
Zacks
LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?
Eli Lilly hits another record high as confidence grows in its obesity and diabetes portfolio, with Wall Street still seeing upside despite the rich valuation.
Zacks
Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now
Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now...
Yahoo! Finance: News
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.
Zacks
Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.
Zacks
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.
Zacks
Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?
Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.
Zacks
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.
Zacks
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?
LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.
Zacks
<
1
2
...
>

Advertisement|Remove ads.